ProShares Trust UltraPro Short QQQ ETF Unusual Bullish Options Activity Means Profits for Traders

 ProShares Trust UltraPro Short QQQ ETF Unusual Bullish Options Activity Means Profits for Traders

In today’s session ProShares Trust UltraPro Short QQQ ETF (SQQQ) registered an unusually high (164) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious SQQQ increase. With 164 contracts traded and 25694 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: SQQQ170120C00015000 closed last at: $0.5 or 28.6% down. About 16,230 shares traded hands. ProShares Trust UltraPro Short QQQ ETF (NASDAQ:SQQQ) has declined 25.72% since April 21, 2016 and is downtrending. It has underperformed by 31.05% the S&P500.

ProShares UltraPro Short QQQ seeks daily investment results, which corresponds to three times the inverse of the daily performance of the NASDAQ-100 Index (the Index). The ETF has a market cap of $554.08 million. The Index includes 100 of the non-financial domestic and international issues listed on National Association of Securities Dealers Automated Quotation (NASDAQ) Stock Market. It currently has negative earnings. The Fund invests in derivatives.

More notable recent ProShares Trust UltraPro Short QQQ ETF (NASDAQ:SQQQ) news were published by: Fool.com which released: “Which Nasdaq ETF is Right for You?” on June 05, 2015, also Etfdailynews.com with their article: “The Best ETFs For A Stock Market Sell-Off” published on March 26, 2013, Benzinga.com published: “ProShares Releases 2 New Leveraged Biotech ETFs” on June 23, 2015. More interesting news about ProShares Trust UltraPro Short QQQ ETF (NASDAQ:SQQQ) were released by: 247Wallst.com and their article: “CAR T-Cell Stocks a Better Way to Leverage Biotech Than New 3x ETFs” published on June 25, 2015 as well as Etftrends.com‘s news article titled: “Finally A Biotech ETF Bounce?” with publication date: June 01, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment